학술논문

Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry.
Document Type
Article
Source
Rheumatology. Mar2022, Vol. 61 Issue 3, p1211-1216. 6p.
Subject
*WEGENER'S granulomatosis diagnosis
*KIDNEY physiology
*EOSINOPHILS
*REPORTING of diseases
*SKIN diseases
*PATIENT aftercare
*PERIPHERAL neuropathy
*WEGENER'S granulomatosis
*EOSINOPHILIA
*DISEASE relapse
*SEX distribution
*DESCRIPTIVE statistics
*SYMPTOMS
Language
ISSN
1462-0324
Abstract
Objective To describe disease presentation and long-term outcome of granulomatosis with polyangiitis (GPA) patients according to blood eosinophils count (Eos) at vasculitis diagnosis. Methods Data from newly diagnosed GPA patients registered in the French Vasculitis Study Group database with available eosinophil count at diagnosis were reviewed. Disease characteristics, rate and type of relapses, and overall survival were analysed according to Eos, categorized as normal (<500/mm3), mild-to-moderate hypereosinophilia (HE) (between 500 and 1500/mm3) and severe HE (>1500/mm3). Results Three hundred and fifty-four patients were included. At diagnosis, 90 (25.4%) patients had HE ≥500/mm3; they were more likely male (73% vs 56%, P  = 0.006) and had more frequent cutaneous manifestations (49% vs 33%, P  = 0.01), peripheral neuropathy (32% vs 17%, P  = 0.004) and higher BVAS (21 vs 18, P  = 0.01), compared with those with Eos <500/mm3. Patients with severe HE (n  = 28; median Eos 2355, range 1500–9114) had more frequent renal function worsening at presentation (P  = 0.008). After a median follow-up of 3.95 (interquartile range 1.95–6.76) years, no difference was found in overall relapse rates according to baseline Eos, but those with HE experienced more neurological (P  = 0.013) and skin (P  = 0.024) relapses and had more frequently peripheral neuropathy as damage at last follow-up (P  = 0.02). Overall survival was not significantly different in patients with normal Eos or HE at diagnosis. (P  = 0.08). Conclusions Blood HE at diagnosis, observed in about one-quarter of GPA patients, identifies a subgroup of patients with a more severe disease and higher rate of skin and neurological involvement both at presentation and during follow-up. [ABSTRACT FROM AUTHOR]